Vaxxas raises $20M in B round

Vaxxas Pty. Ltd. (Sydney, Australia) raised $20 million (A$25.7 million) toward a planned $23.3 million (A$30 million) series B round led by existing investor OneVentures. Undisclosed new investors also participated.

CEO David Hoey said the company plans to begin clinical testing this year of its needle-free Nanopatch technology to deliver an approved flu vaccine with an undisclosed partner. Vaxxas has received funding from the World Health Organization to perform preclinical studies using Nanopatch to deliver polio vaccine. ...